The technology, which uses a
derivative of a human gene to deliver anti-tumour agents to
the site of the tumour, will form a component of Oxford BioMedica's
first anti-cancer product MetXiaT, due to enter Phase I/II
clinical trials towards the end of next year. Commenting on
the news, Professor Alan Kingsman, Oxford BioMedica's Chief
Executive, said: 'We are delighted to be working alongside
such a prestigious group of clinical centres and it is, of
course, a powerful endorsement of our technical and commercial
strength. We anticipate a long interaction with our colleagues
in Boston that will lead to a range of product opportunities.'
Andrew Wood Finance Director,
added: 'Further details on the technology and the MetXia trial
will be announced once the numerous commercial opportunities
relating to the new technology have been fully explored.'
Notes to Editors
1. Oxford BioMedica, established
in 1995, specialises in the development and application of
gene-based therapeutics using advanced gene delivery technologies
for the treatment of disease in the areas of: oncology, viral
infection, neurobiology and genetic deficiency. Oxford BioMedica
plc was floated on the UK Alternative Investment Market of
the London Stock Exchange in December 1996.
2. Further information on Oxford
BioMedica can be obtained from its website: http://www.oxfordbiomedica.co.uk
